201 related articles for article (PubMed ID: 34903705)
1. In Vitro Comparison of Recombinant and Plasma-Derived von Willebrand Factor Concentrate for Treatment of Acquired von Willebrand Syndrome in Adult Extracorporeal Membrane Oxygenation Patients.
Mazzeffi M; Henderson R; Krause E; Rabin J; Madathil R; Chow J; Grazioli A; Meyer M; Wu Z; Tanaka K
Anesth Analg; 2022 Feb; 134(2):312-321. PubMed ID: 34903705
[TBL] [Abstract][Full Text] [Related]
2. Von Willebrand Factor Concentrate Administration for Acquired Von Willebrand Syndrome- Related Bleeding During Adult Extracorporeal Membrane Oxygenation.
Mazzeffi M; Bathula A; Tabatabai A; Menaker J; Kaczorowski D; Madathil R; Galvagno S; Pasrija C; Rector R; Tanaka K; Herr D
J Cardiothorac Vasc Anesth; 2021 Mar; 35(3):882-887. PubMed ID: 32758410
[TBL] [Abstract][Full Text] [Related]
3. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
4. Von Willebrand Factor-GP1bα Interactions in Venoarterial Extracorporeal Membrane Oxygenation Patients.
Mazzeffi M; Hasan S; Abuelkasem E; Meyer M; Deatrick K; Taylor B; Kon Z; Herr D; Tanaka K
J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2125-2132. PubMed ID: 30595484
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
Lethagen S; Kyrle PA; Castaman G; Haertel S; Mannucci PM;
J Thromb Haemost; 2007 Jul; 5(7):1420-30. PubMed ID: 17439628
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
Tauber H; Ott H; Streif W; Weigel G; Loacker L; Fritz J; Heinz A; Velik-Salchner C
Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
[TBL] [Abstract][Full Text] [Related]
11. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
Hillarp A; Friedman KD; Adcock-Funk D; Tiefenbacher S; Nichols WL; Chen D; Stadler M; Schwartz BA
Haemophilia; 2015 Nov; 21(6):837-45. PubMed ID: 26172561
[TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
[TBL] [Abstract][Full Text] [Related]
13. Impact of extracorporeal membrane oxygenation treatments on acquired von Willebrand syndrome in patients with out-of-hospital cardiac arrest: a retrospective observational study.
Chiba Y; Goto K; Suzuki M; Horiuchi H; Hayakawa M
Thromb J; 2024 May; 22(1):46. PubMed ID: 38822325
[TBL] [Abstract][Full Text] [Related]
14. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
Fricke WA; Brinkhous KM; Garris JB; Roberts HR
Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal membrane oxygenation seems to induce impairment of primary hemostasis pathology as measured by a Multiplate analyzer: An observational retrospective study.
Garaj M; Durila M; Vajter J; Solcova M; Marecek F; Hrachovinová I
Artif Organs; 2022 May; 46(5):899-907. PubMed ID: 34904233
[TBL] [Abstract][Full Text] [Related]
16. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
Weiss HJ; Sussman II
Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
Windyga J; von Depka-Prondzinski M;
Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
[TBL] [Abstract][Full Text] [Related]
18. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
19. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: Rapid onset and fast recovery.
Kalbhenn J; Schlagenhauf A; Rosenfelder S; Schmutz A; Zieger B
J Heart Lung Transplant; 2018 Aug; 37(8):985-991. PubMed ID: 29650295
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
